Stauprimide inhibits c-myc transcription in cancer cells
Stauprimide is known to prime Embryonic Stem Cells (ESC) by targeting the c-Myc-activating transcription factor NME2. Its mechanism of action is linked to the inhibition of the nuclear localization of NME2 leading to the downregulation of the transcription of the c-myc oncogene.
In a recent study, Bouvard C. et al. evidenced that Stauprimide’s mechanism of action could also be used to pharmacologically targetc-myc transcription in cancers.
To validate this hypothesis, the authors downregulated the transcription of the c-myc oncogene in RXF393 cancer cell lines (Human Kidney Renal Cell Carcinoma) via the inhibition of NME2 nuclear localization. In parallel, this staurosporine analog also inhibited tumour growth in xenograft models.
The authors concluded thus that stauprimide might provide an effective and unique anticancer strategy for c-myc dependent tumours.
Bouvard C. et al. “Small molecule selectively suppresses MYC transcription in cancer cells” (2017) PNAS, Vol. 114 No. 13, pp. 3497–3502 (doi: 10.1073/pnas.1702663114
Looking for Stauprimide for research applications?
- CAS number: 154589-96-5
- Molecular Weight: 584.64
- Molecular Formula: C35H28N4O5
- Purity: 98% by TLC – NMR (Conforms)
- Soluble in DMSO (up to 20 mg/ml)
Learn more about tools like this by subscribing to thematic newsletters on your favourite research topics
Are you looking for a particular small molecule?
Leave your questions below!